Literature DB >> 2849001

Immune changes in male homosexuals--predisposing factors for HIV seroconversion.

Z Bentwich1, R Burstein, Y Berner, T Gotlieb-Stematsky, A Vonsover, Z Handzel.   

Abstract

Israel is still a low incidence country for AIDS and thus the temporal relationships between various cofactors and HIV infection can be more easily determined. We have studied a cohort of 243 asymptomatic male homosexuals (MHS) during the last 4 years. At the beginning of the study, 40% had significant decreases in the peripheral blood lymphoid populations, signs for reactivation of CMV and EBV infections, and elevated serum levels of interferon. There was no difference in the prevalence of these immune derangements between seropositive and seronegative individuals. In the course of 4 years' follow-up, the prevalence of these immune derangements has remained the same though being significantly more severe in the HIV seropositive subjects. HIV seroconversion did not exceed 8% (about 2% annually) and was related to the immune impairments found when first seen at the beginning of the study. The results suggest that immune impairments are common among asymptomatic MHS, precede HIV infection, and probably contribute to the increased risk for AIDS among male homosexuals.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2849001

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  2 in total

1.  Sequential serological studies of homosexual men with and without HIV infection. Epstein-Barr virus activation preceding and following HIV seroconversion.

Authors:  A Schattner; N Hanuka; B Sarov; I Sarov; Z Handzel; Z Bentwich
Journal:  Clin Exp Immunol       Date:  1991-08       Impact factor: 4.330

2.  Prevalence of antibodies to human herpesviruses and hepatitis B virus in patients at different stages of human immunodeficiency virus (HIV) infection.

Authors:  R Enzensberger; W Braun; C July; E B Helm; H W Doerr
Journal:  Infection       Date:  1991 May-Jun       Impact factor: 3.553

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.